CellectisのROCE
CellectisのROCEは何ですか。
CellectisのROCEは-53.69%です。
ROCEの定義は何ですか。
使用資本利益率(ROCE)は、企業の収益性とその資本が使用される効率を測定する財務比率です。
Return on capital employed (ROCE) is the total amount of capital that a company has utilized in order to generate profits. It is the sum of shareholders' equity and debt liabilities. It can be simplified as total assets minus current liabilities.
ROCE is especially useful when comparing the performance of companies in capital-intensive sectors. ROCE considers debt and other liabilities as well compared to other fundamentals which only analyze profitability related to a company’s common equity. This provides a better indication of financial performance for companies with significant debt. For a company, the ROCE trend over the years is also an important indicator of performance. In general, investors tend to favor companies with stable and rising ROCE numbers over companies where ROCE is volatile and bounces around from one year to the next.
Instead of using capital employed at an arbitrary point in time, analysts and investors often calculate ROCE based on the average capital employed (ROACE), which takes the average of opening and closing capital employed for the time period.
NASDAQのセクタHealth CareにおけるROCEの企業と比べるCellectis
Cellectisは何をしますか。
cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited t-cells (ucart). by capitalizing on its 18 years of expertise in gene editing – built on its flagship talen® technology and pioneering electroporation system pulseagile – cellectis uses the power of the immune system to target and eradicate cancer cells. using its life-science-focused, pioneering genome engineering technologies, cellectis’ goal is to create innovative products in multiple fields and with various target markets. cellectis is listed on the nasdaq market (ticker: clls) and on the nyse alternext market (ticker: alcls). to find out more about us, visit our website: www.cellectis.com talking about gene editing? we do it. talen® is a registered trademark owned by the cellectis group.
Cellectisと類似のroce
- Continental MaterialsのROCEは-53.90%です。
- CuriosityStreamのROCEは-53.88%です。
- Personalis IncのROCEは-53.75%です。
- Lexicon Pharmaceuticals IncのROCEは-53.73%です。
- OncocyteのROCEは-53.73%です。
- Berkeley LightsのROCEは-53.73%です。
- CellectisのROCEは-53.69%です。
- Pacifico MineralsのROCEは-53.63%です。
- SpringWorks TherapeuticsのROCEは-53.49%です。
- Profound Medical CorpのROCEは-53.48%です。
- QC Copper and GoldのROCEは-53.41%です。
- Minaurum GoldのROCEは-53.40%です。
- Angus VenturesのROCEは-53.35%です。